Nakaya Aya, Fujita Shinya, Satake Atsushi, Nakanishi Takahisa, Azuma Yoshiko, Tsubokura Yukie, Saito Ryo, Konishi Akiko, Hotta Masaaki, Yoshimura Hideaki, Ishii Kazuyoshi, Ito Tomoki, Nomura Shosaku
First Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, Japan.
Oncol Lett. 2020 Feb;19(2):1317-1321. doi: 10.3892/ol.2019.11225. Epub 2019 Dec 18.
Patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) have exhibited improved overall survival. However, information on AZA in real-world settings is limited. The present study retrospectively analyzed 85 patients with MDS treated with AZA. Complete response was achieved in 24% of cases and hematologic improvement in 29%. Severe adverse events (grade ≥3) included neutropenia and infection. Multivariate analysis identified higher revised international prognostic scoring system (IPSS-R) and male sex as significant factors affecting survival. However, the present study did not identify any significant associations between patient characteristics and response to AZA. In conclusion, AZA could produce a hematologic response in ~53% of patients with MDS. Furthermore, IPSS-R may reflect MDS prognosis. Further studies are required to establish the criteria for identifying patients likely to obtain maximum benefit from AZA treatment.
接受阿扎胞苷（AZA）治疗的高危骨髓增生异常综合征（MDS）患者的总生存期有所改善。然而，关于AZA在实际临床环境中的信息有限。本研究回顾性分析了85例接受AZA治疗的MDS患者。24%的病例达到完全缓解，29%出现血液学改善。严重不良事件（≥3级）包括中性粒细胞减少和感染。多因素分析确定较高的修订国际预后评分系统（IPSS-R）和男性为影响生存的显著因素。然而，本研究未发现患者特征与对AZA的反应之间存在任何显著关联。总之，AZA可使约53%的MDS患者产生血液学反应。此外，IPSS-R可能反映MDS的预后。需要进一步研究以确立识别可能从AZA治疗中获得最大益处的患者的标准。
